GrantsNovel Technology for Intervening in Non-Compressible Haemorrhage

Novel Technology for Intervening in Non-Compressible Haemorrhage

Award: Share of up to £1.5 million

Programme: DASA (Defence and Security Accelerator) on behalf of Defence Medical Services (DMS) and UKRI

Closing date: 4 November 2025

Overview

This competition seeks novel, device-based innovations that can intervene to stop non-compressible haemorrhage (NCH) in the prehospital setting, for both combat and civilian contexts. The focus is on technologies currently at Technology Readiness Levels (TRL) 2 to 4, with the expectation of progressing one or more TRLs during the funded project.

Non-compressible haemorrhage refers to internal or anatomical bleeding that cannot be effectively managed by external pressure alone. It remains a leading cause of potentially preventable death in trauma settings.

The competition encourages engineering, design-led interventions that integrate novel approaches (including repurposing technologies from non-healthcare sectors) for effective bleeding control near the point of injury, usable by non-specialist medical providers.

Eligibility & Scope

  • Proposals must target TRL 2–4 at project start (innovations beyond TRL 4 are out of scope).
  • Interventions must aim to stop bleeding, not merely detect it or serve as incremental enhancements of existing prehospital techniques.
  • Innovations must be operable near point-of-injury by non-specialist medical providers (military or civilian).
  • Dual-use applications (military + civilian) are encouraged.
  • The project duration may be up to 48 months, targeting an April 2026 start if possible.
  • Applicants may come from academia, public sector research establishments, or the private sector. Normal checking of legal status and eligibility will apply.
  • Applicants must comply with terms & conditions, including export control, regulatory, ethical, and cybersecurity aspects.
  • Proposals incorporating detection/localisation may be considered if the core capability includes haemostatic action (i.e. stopping bleeding). Pure detection-focused solutions are out of scope.

Award & Project Duration

  • Award: Share of up to £1.5 million.
  • Projects Duration: Up to 48 months.

Key Dates

  • Closes: 4th November 2025

Alternatively

Give us a ring on or drop us an email at . Our offices might
be based in UK, but we proudly serve clients across the UK and Europe.